Physician profile
Noffar Bar
NPI 1215179106
$6,587.63
in general payments reported to CMS, 2019-2025
9 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,186 · 2023: $860 · 2024: $1,300 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,138 · Food and Beverage: $1,019 · Travel and Lodging: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,137.50 |
| Food and Beverage | $1,019.15 |
| Travel and Lodging | $245.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,857.50 | 2022-2024 | Carvykti |
| Janssen Biotech, INC. | $2,469.36 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $569.02 | 2022-2025 | |
| Janssen Research & Development, LLC | $404.69 | 2023 | Carvykti |
| Seagen INC. | $242.17 | 2022-2023 | |
| Sanofi Pasteur INC. | $44.89 | 2024-2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noffar Bar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.